Gene Security Network Completes Funding to Expand Into New DNA Testing Markets

November 1, 2010  source: Gene Security Network (download the pdf press release)

REDWOOD CITY, CA – November 1, 2010 – Gene Security Network, Inc. (GSN) today announced the closing of its $12M Series C financing. The financing round was led by Sequoia Capital and included Claremont Creek Ventures, Founders Fund, and Lightspeed Venture Partners.

GSN is a molecular diagnostics company using data informatics to enhance genetic testing of DNA. GSN has established a leadership position in the in vitro fertilization market (IVF) where its proprietary Parental SupportTM technology diagnoses the genetic state of a single cell from an embryo.

“I am pleased that this outstanding syndicate of investors, led by Sequoia, share our mission of helping people worldwide have healthy children,” said Matthew Rabinowitz, Ph.D., President and CEO of Gene Security Network. “The new investment will accelerate the application of our technology beyond the fertility market, into areas such as prenatal diagnostics which crucially needs tests with enhanced accuracy and coverage.”

Over four million births occur in the United States each year. Over one percent of these births result from in vitro fertilization (IVF), with over 138,000 IVF cycles occurring annually. Regardless of whether a child is conceived by IVF or traditional means, there is a 3‐5% rate of birth defects or genetic illness.

“GSN has been able to rapidly commercialize its unique Parental Support technology across multiple applications in the invitro fertilization market and is now in a strong position to expand and deliver revolutionary tools to the broader reproductive industry,” said Roelof Botha, Partner at Sequoia Capital. “Sequoia is pleased to lead this round and I very much look forward to being involved in the success of the company.”

Couples undergoing IVF have been using GSN’s Parental Support technology since 2008 for preimplantation genetic diagnosis (PGD) to help identify embryos free of genetic disease prior to transfer to the mother’s uterus. Testing is available through most leading IVF clinics in the United States with recent expansion into international markets. The accuracy of the Parental Support diagnostic and biology it has revealed about the human embryo have been published in the journal Human Reproduction. Clinical outcomes for couples using the technology were recently presented at the American Society of Reproductive Medicine annual meeting in Denver, Colorado.

About Gene Security Network

Gene Security Network is a privately held molecular diagnostics company that develops technologies for complex testing of small quantities of genetic material. GSN’s

proprietary Parental SupportTM technology is the first to leverage data informatics to deliver highly accurate single cell testing for chromosome abnormalities and genetic diseases. Parental SupportTM uses genetic information from the parents, as well as HapMap data from the Human Genome Project, to clarify the typically noisy measurements from a single cell and to generate an in silico reconstruction of the cell’s genotype. GSN operates a CLIA‐certified laboratory in Redwood City, California, providing preimplantation genetic diagnosis (PGD) testing services to guide doctors in selecting embryos during in vitro fertilization. For more information, please visit www.genesecurity.net.

Reader Interactions

Comments

Reader Interactions

Comments